Teleflex Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Liam Kelly

Chief Executive Officer (CEO)

US$9.0m

Compensación total

Porcentaje del salario del CEO	11.7%
Permanencia del CEO	8yrs
Participación del CEO	0.06%
Permanencia media de la dirección	4.1yrs
Promedio de permanencia en la Junta Directiva	6.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Liam Kelly en comparación con los beneficios de Teleflex?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$296m
Dec 31 2023	US$9m	US$1m	US$358m
Oct 01 2023	n/a	n/a	US$405m
Jul 02 2023	n/a	n/a	US$369m
Apr 02 2023	n/a	n/a	US$363m
Dec 31 2022	US$8m	US$1m	US$363m
Sep 25 2022	n/a	n/a	US$412m
Jun 26 2022	n/a	n/a	US$510m
Mar 27 2022	n/a	n/a	US$488m
Dec 31 2021	US$9m	US$982k	US$485m
Sep 26 2021	n/a	n/a	US$434m
Jun 27 2021	n/a	n/a	US$351m
Mar 28 2021	n/a	n/a	US$280m
Dec 31 2020	US$6m	US$943k	US$336m
Sep 27 2020	n/a	n/a	US$367m
Jun 28 2020	n/a	n/a	US$479m
Mar 29 2020	n/a	n/a	US$551m
Dec 31 2019	US$7m	US$869k	US$462m
Sep 29 2019	n/a	n/a	US$442m
Jun 30 2019	n/a	n/a	US$269m
Mar 31 2019	n/a	n/a	US$183m
Dec 31 2018	US$6m	US$846k	US$196m
Sep 30 2018	n/a	n/a	US$66m
Jul 01 2018	n/a	n/a	US$89m
Apr 01 2018	n/a	n/a	US$170m
Dec 31 2017	US$3m	US$617k	US$155m

Compensación vs. Mercado: La compensación total de Liam($USD9.04M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD5.57M).

Compensación vs. Ingresos: La compensación de Liam ha sido consistente con los resultados de la empresa en el último año.

CEO

Liam Kelly (56 yo)

8yrs

Permanencia

US$9,039,947

Compensación

Mr. Liam J. Kelly has been Chief Executive Officer at Teleflex Incorporated since January 01, 2018 and has been its Director since May 4, 2018. He serves as Independent Director of Enovis Corporation (form...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Liam Kelly	Chairman	8yrs	US$9.04m	0.059% $ 5.3m
Thomas Powell	Executive VP & CFO	12.2yrs	US$3.53m	0.022% $ 2.0m
Daniel Logue	Corporate VP	3.3yrs	US$1.81m	0.021% $ 1.9m
Jay White	Corporate VP & President of Global Commercial	3.3yrs	US$2.37m	0.0070% $ 621.8k
John Deren	Corporate VP & Chief Accounting Officer	7yrs	sin datos	0.0042% $ 375.7k
Timothy Duffy	VP & Chief Information Officer	no data	sin datos	sin datos
Howard Cyr	Corporate VP & Chief Compliance Officer	2.5yrs	sin datos	sin datos
Cameron Hicks	Corporate Vice President of Human Resources & Communications	11.1yrs	US$1.34m	0.016% $ 1.4m
James Ferguson	President & GM of Surgical	no data	sin datos	sin datos
Michelle Fox	Corporate VP & Chief Medical Officer	4.3yrs	sin datos	sin datos
Matthew James	President	3.9yrs	sin datos	sin datos
Jake Newman	President of The Americas	3.3yrs	sin datos	sin datos

4.1yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de TBH se considera experimentado (4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Liam Kelly	Chairman	6yrs	US$9.04m	0.059% $ 5.3m
John Heinmiller	Independent Director	5.3yrs	US$308.20k	0.0060% $ 530.3k
Gretchen Frances Haggerty	Independent Director	7.7yrs	US$308.20k	0.0076% $ 675.1k
Stuart Randle	Independent Director	15yrs	US$324.53k	0.0092% $ 814.5k
Andrew Krakauer	Independent Director	6.3yrs	US$303.28k	0.0095% $ 842.9k
Stephen Klasko	Independent Lead Director	16yrs	US$350.30k	0.017% $ 1.5m
Candace Duncan	Independent Director	9yrs	US$313.82k	0.0086% $ 762.1k
Jaewon Ryu	Independent Director	less than a year	US$364.30k	sin datos
Neena Patil	Independent Director	2.1yrs	US$301.20k	0.00085% $ 75.5k

6.3yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: La junta directiva de TBH se considera experimentada (6.3 años de antigüedad promedio).

Teleflex Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Teleflex Incorporated, Annual General Meeting, May 03, 2024

Insufficient new directors

Insufficient new directors

Teleflex Incorporated, Annual General Meeting, Apr 29, 2022

Teleflex Incorporated Announces Board Changes

Insufficient new directors

Recent updates

Teleflex Incorporated Raises Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$0.33 (vs US$1.65 in 1Q 2023)

Teleflex Incorporated, Annual General Meeting, May 03, 2024

Fourth quarter dividend of US$0.34 announced

Full year 2023 earnings released: EPS: US$7.61 (vs US$7.74 in FY 2022)

Teleflex Incorporated Announces Quarterly Dividend, Payable on March 15, 2024

Teleflex Incorporated Offers Its Titan SGS Stapler with Staple Line Reinforcement

Teleflex Incorporated Announces First Patient Enrollment in ACCESS-MANTA Registry

Teleflex Incorporated Announces A New Peer-Reviewed Study in the Nature Journal Prostate Cancer and Prostatic Diseases Confirms the Position of the UroLift System as the Gold Standard in Minimally Invasive Surgical Treatment

Teleflex Incorporated Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$2.93 (vs US$2.17 in 3Q 2022)

Teleflex Incorporated (NYSE:TFX) acquired Palette Life Sciences for $650 million.

Teleflex Incorporated (NYSE:TFX) acquired Palette Life Sciences for $650 million.

Teleflex Incorporated Announces Extension of Arrow ErgoPack Complete System to Hemodialysis and Large Bore Central Venous Catheters

Upcoming dividend of US$0.34 per share at 0.6% yield

Teleflex Incorporated Updates Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$2.37 (vs US$2.25 in 2Q 2022)

Teleflex Incorporated Receives FDA Clearance for Expanded Indication for QuikClot Control+(TM) Hemostatic Device Usage in Cardiac Surgical Procedures

Teleflex Incorporated (NYSE:TFX) entered into a definitive agreement to acquire Palette Life Sciences AB for $650 million.

Teleflex Incorporated (NYSE:TFX) entered into a definitive agreement to acquire Palette Life Sciences AB from Östersjöstiftelsen, Endowment Arm, Praktikerinvest AB and Recipharm Venture Fund AB for $650 million.

Teleflex Incorporated Receives FDA Clearance for the Wattson Temporary Pacing Guidewire

Teleflex Incorporated Announces the Arrow(R) EZ-Io(R) Needle Is Now FDA Cleared for Use in an MRI Environment

Teleflex Announces Quarterly Dividend, June 15, 2023

Teleflex Incorporated Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released: EPS: US$1.65 (vs US$1.65 in 1Q 2022)

Full year 2022 earnings released: EPS: US$7.74 (vs US$10.37 in FY 2021)

Insufficient new directors

Upcoming dividend of US$0.34 per share

Teleflex Incorporated Announces Worldwide Recall of Affected Lots of Gibeck Iso-Gard Filter Products

Third quarter 2022 earnings released: EPS: US$2.17 (vs US$4.26 in 3Q 2021)

Teleflex Incorporated Revises Earnings Guidance for the Year 2022

Teleflex Incorporated (NYSE:TFX) completed the acquisition of Standard Bariatrics, Inc.

Teleflex Incorporated Launches New Arrow® Pressure Injectable Midline Catheter Portfolio

Teleflex Incorporated (NYSE:TFX) entered into a definitive agreement to acquire Standard Bariatrics, Inc. for $300 million.

Upcoming dividend of US$0.34 per share

Second quarter 2022 earnings released: EPS: US$2.25 (vs US$1.78 in 2Q 2021)

Teleflex Incorporated Provides Earnings Guidance for the Full Year of 2022

Teleflex Incorporated (NYSE:TFX) acquired unknown stake in Traverse Vascular Inc.

Teleflex Incorporated Announces First Patient Enrollment in MANTA Ultra Study

Teleflex Launches New Arrow Pressure Injectable Midline Catheter in Australia and New Zealand

Teleflex Incorporated Launches New Arrow Pressure Injectable Midline Catheter in Europe, the Middle East and Africa Region

Teleflex Incorporated Reaffirms Earnings Guidance for the Full Year of 2022

Teleflex Incorporated Announces Regulatory Clearance for Its Urolift® System in China for the Treatment of Benign Prostatic Hyperplasia

Teleflex Announces Health Canada Approval of MANTA® Vascular Closure Device

Teleflex Incorporated Declares Quarterly Cash Dividend, Payable on June 15, 2022

First quarter 2022 earnings released: EPS: US$1.65 (vs US$1.60 in 1Q 2021)

Insufficient new directors

Teleflex Announces the Launch of the UroLift® System in Japan for the Treatment of Benign Prostatic Hyperplasia

Teleflex Incorporated, Annual General Meeting, Apr 29, 2022

Teleflex Incorporated Announces Board Changes

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Teleflex Incorporated Declares Quarterly Cash Dividend, Payable March 15, 2022

Teleflex Receives FDA Clearance for Expanded Indication for Specialty Catheter and Coronary Guidewire Use in CTO PCI Procedures

Insufficient new directors

Independent Director recently bought €273k worth of stock

Upcoming dividend of US$0.34 per share

Third quarter 2021 earnings released: EPS US$4.26 (vs US$2.51 in 3Q 2020)

Teleflex Announces Large-Scale Analysis of Real-World Healthcare Claims Data for Enlarged Prostate Procedures At the American Urological Association 2021 Annual Meeting

Teleflex Unveils the UroLift Advanced Tissue Control System and the UroLift 2 System

Teleflex Incorporated Announces New Study Provides Insights into the Biocompatibility and Durability of the UroLiftSystem in Improving Benign Prostatic Hyperplasia Symptoms

Upcoming dividend of US$0.34 per share

Second quarter 2021 earnings released: EPS US$1.78 (vs US$0.25 in 2Q 2020)

Medline Industries, Inc. completed the acquisition of Certain product lines of global respiratory product portfolio of Teleflex Incorporated.

Medline Industries, Inc. entered into a definitive agreement to acquire Certain product lines of global respiratory product portfolio from Teleflex Incorporated (NYSE:TFX) for approximately $270 million.

Upcoming dividend of US$0.34 per share

Teleflex Incorporated Declares Quarterly Cash Dividend, Payable on June 15, 2021

First quarter 2021 earnings released: EPS US$1.60 (vs US$2.83 in 1Q 2020)

New 90-day high: €340

Teleflex Incorporated Reports 250,000 Patients Treated for Enlarged Prostate With the Minimally Invasive UroLift® System